https://mindmedicinelaw.com/briefing/challenge-to-psilocybin-ballot-measure-in-joseph-oregon-20260828-36375The Psychedelic Journalen2026-08-28T15:07:16.608250+00:00Challenge to Psilocybin Ballot Measure in Joseph, Oregonpsilocybin regulation, Joseph Oregon, legal challenge, ballot measure, psychedelic policy, community debate, Oregon Measure 109, local jurisdiction, therapeutic use, public safetyhttps://mindmedicinelaw.com/briefing/tampa-bay-expands-ketamine-access-for-veterans-with-ptsd-20260828-36374The Psychedelic Journalen2026-08-28T15:06:16.046402+00:00Tampa Bay Expands Ketamine Access for Veterans with PTSDketamine therapy, PTSD treatment, veterans mental health, Tampa Bay, psychedelic-assisted therapy, mental health policy, glutamate modulation, psychedelic research, clinical trials, public health initiativeshttps://mindmedicinelaw.com/briefing/olfm1-gene-hypomethylation-a-new-biomarker-for-depression-20260827-36308The Psychedelic Journalen2026-08-28T15:07:35.315543+00:00OLFM1 Gene Hypomethylation: A New Biomarker for DepressionOLFM1 gene, hypomethylation, depression biomarker, epigenetics, psychedelic research, genetic markers, mental health, DNA methylation, psychiatric disorders, personalized medicinehttps://mindmedicinelaw.com/briefing/psilocybin-for-trd-amcp-panel-insights-and-implications-20260827-36262The Psychedelic Journalen2026-08-28T15:06:30.325427+00:00Psilocybin for TRD: AMCP Panel Insights and Implicationspsilocybin, treatment-resistant depression, AMCP panel, managed care, mental health, clinical trials, payer decisions, health policy, psychedelic therapy, healthcare networkhttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-service-centers-safety-and-cost-challenges-20260827-36263The Psychedelic Journalen2026-08-28T15:05:59.477403+00:00Oregon's Psilocybin Service Centers: Safety and Cost ChallengesOregon psilocybin service centers, psychiatric assessment, psilocybin safety protocols, financial barriers in psilocybin services, psilocybin accessibility, psilocybin policy implications, psilocybin service model, psilocybin therapy costs, psilocybin research, psilocybin legal frameworkhttps://mindmedicinelaw.com/briefing/high-dose-thc-vs-psilocybin-pilot-study-in-therapeutic-context-20260827-36138The Psychedelic Journalen2026-08-27T22:04:56.955491+00:00High Dose THC vs Psilocybin: Pilot Study in Therapeutic ContextTHC, psilocybin, psychedelic therapy, set and setting, clinical trials, psychopharmacology, therapeutic applications, psychoactive substances, dronabinol, cannabis distillatehttps://mindmedicinelaw.com/briefing/dea-classifies-cipepofol-as-schedule-iv-substance-20260827-35918The Psychedelic Journalen2026-08-27T15:05:25.294442+00:00DEA Classifies Cipepofol as Schedule IV Substancecipepofol, DEA, Schedule IV, controlled substances, general anesthesia, FDA approval, drug policy, psychoactive substances, clinical research, medical regulationhttps://mindmedicinelaw.com/briefing/dea-temporarily-schedules-new-substances-in-schedule-i-20260827-35919The Psychedelic Journalen2026-08-27T15:05:09.553305+00:00DEA Temporarily Schedules New Substances in Schedule IDEA, Schedule I, controlled substances, 5,6-dichloro brorphine, psychedelic research, public safety, regulatory controls, drug policy, market impact, research restrictionshttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-therapy-milestone-20-000-treated-20260827-36064The Psychedelic Journalen2026-08-27T15:04:57.854123+00:00Oregon's Psilocybin Therapy Milestone: 20,000 Treatedpsilocybin therapy, Oregon psychedelic policy, mental health treatment, psychedelic research, psilocybin legalization, therapeutic benefits, psychedelic therapy risks, psilocybin outcomes, mental health innovation, psilocybin investmenthttps://mindmedicinelaw.com/briefing/bdnf-trkb-mtor-axis-and-depression-new-insights-20260826-36309The Psychedelic Journalen2026-08-28T15:08:11.872894+00:00BDNF–TrkB–mTOR Axis and Depression: New InsightsBDNF, TrkB, mTOR, depression, neuroinflammation, oxidative stress, neurotrophic factors, psychiatric treatment, mental health, biomarkershttps://mindmedicinelaw.com/briefing/ipsc-derived-models-psychiatry-insights-challenges-20260826-36312The Psychedelic Journalen2026-08-28T15:07:54.804270+00:00iPSC-Derived Models: Psychiatry Insights & ChallengesiPSC-derived models, psychiatric disorders, precision psychiatry, genetic risks, neural differentiation, patient stratification, functional phenotyping, translational research, polygenic architecture, ethical considerationshttps://mindmedicinelaw.com/briefing/ketamine-in-treating-resistant-depression-efficacy-and-risks-20260826-36313The Psychedelic Journalen2026-08-28T15:06:51.312968+00:00Ketamine in Treating Resistant Depression: Efficacy and Risksketamine, treatment-resistant depression, esketamine, rapid-acting antidepressants, glutamatergic neurotransmission, clinical trials, FDA approval, adverse effects, long-term safety, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/rapamycin-augments-ketamine-subjective-gains-in-study-20260826-36154The Psychedelic Journalen2026-08-27T22:06:01.936826+00:00Rapamycin Augments Ketamine: Subjective Gains in Studyrapamycin, ketamine, psychedelic research, biochemical variability, clinical trials, mTOR inhibitor, biomarkers, treatment protocols, patient selection, randomized trialshttps://mindmedicinelaw.com/briefing/small-molecules-in-pain-and-mental-health-care-emerging-trends-20260826-36153The Psychedelic Journalen2026-08-27T22:05:50.479509+00:00Small Molecules in Pain and Mental Health Care: Emerging Trendssmall molecules, pain management, mental health, neuropharmacology, ketamine, treatment-resistant depression, neurological conditions, clinical trials, therapeutic strategies, side effectshttps://mindmedicinelaw.com/briefing/next-gen-pharmacotherapies-for-mood-disorders-in-phase-ii-iii-trials-20260826-36139The Psychedelic Journalen2026-08-27T22:05:39.595825+00:00Next-Gen Pharmacotherapies for Mood Disorders in Phase II/III Trialsunipolar mood disorders, pharmacotherapy, clinical trials, neuroplasticity, serotonin receptor modulation, NMDA receptor, FDA, drug development, mental health, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/federal-report-urges-states-to-prepare-for-psychedelics-20260826-35909The Psychedelic Journalen2026-08-26T22:03:52.741674+00:00Federal Report Urges States to Prepare for Psychedelicspsychedelic approval, FDA, state regulation, mental health, therapeutic use, policy framework, public health, psilocybin, MDMA, federal reporthttps://mindmedicinelaw.com/briefing/stress-substance-use-and-brain-white-matter-new-insights-20260825-36158The Psychedelic Journalen2026-08-28T15:08:30.774128+00:00Stress, Substance Use, and Brain White Matter: New Insightsstress hormones, substance use disorder, brain white matter, cortisol response, longitudinal study, biomarkers, substance use involvement, white matter microstructure, cingulum, youth interventionhttps://mindmedicinelaw.com/briefing/the-role-of-social-environments-in-psychedelic-treatments-20260825-36106The Psychedelic Journalen2026-08-27T22:06:35.869794+00:00The Role of Social Environments in Psychedelic Treatmentspsychedelic treatments, social environments, clinical intensity, psychoeducation, peer support, treatment outcomes, integration support, patient care strategies, research protocols, support networkshttps://mindmedicinelaw.com/briefing/creatine-s-emerging-role-in-cognitive-and-psychiatric-health-20260825-36159The Psychedelic Journalen2026-08-27T22:06:22.055729+00:00Creatine's Emerging Role in Cognitive and Psychiatric Healthcreatine monohydrate, cognitive enhancement, unipolar depression, psychiatric treatment, metabolic stress, randomized controlled trials, biological sex, mental health, neuroscience, supplementationhttps://mindmedicinelaw.com/briefing/tryptophan-metabolism-and-depression-new-insights-20260825-36157The Psychedelic Journalen2026-08-27T22:06:11.781785+00:00Tryptophan Metabolism and Depression: New Insightstryptophan metabolism, major depressive disorder, microbiota-gut-brain axis, treatment-resistant depression, kynurenine pathway, serotonin pathway, indole pathway, biomarker profiles, precision medicine, clinical trialshttps://mindmedicinelaw.com/briefing/esketamine-enhances-post-hip-surgery-analgesia-in-elderly-patients-20260825-36156The Psychedelic Journalen2026-08-27T22:05:09.763499+00:00Esketamine Enhances Post-Hip Surgery Analgesia in Elderly Patientsesketamine, postoperative analgesia, elderly patients, total hip arthroplasty, fascia iliaca compartment block, pain management, clinical trials, anesthetic consumption, patient satisfactionhttps://mindmedicinelaw.com/briefing/comparing-state-psilocybin-regulatory-frameworks-in-the-u-s-20260825-36109The Psychedelic Journalen2026-08-27T22:04:40.585281+00:00Comparing State Psilocybin Regulatory Frameworks in the U.S.psilocybin regulation, state regulatory frameworks, Oregon psilocybin policy, Colorado psilocybin model, New Mexico clinician-directed, Indigenous practice protections, public health and safety, psilocybin accessibility, federal interference risks, therapeutic potentialhttps://mindmedicinelaw.com/briefing/wearable-vagus-nerve-stimulation-a-new-frontier-in-depression-treatment-20260825-35954The Psychedelic Journalen2026-08-27T15:06:07.804415+00:00Wearable Vagus Nerve Stimulation: A New Frontier in Depression Treatmentwearable vagus nerve stimulation, depression treatment, non-invasive neuromodulation, AI in healthcare, personalized therapy, clinical trials, bioelectronics, mental health technology, neuromodulation devices, public health policyhttps://mindmedicinelaw.com/briefing/salvinorin-a-human-trials-reveal-unique-safety-and-efficacy-20260825-35986The Psychedelic Journalen2026-08-27T15:05:55.582225+00:00Salvinorin A: Human Trials Reveal Unique Safety and Efficacysalvinorin A, κ-opioid receptor, psychedelic research, pharmacokinetics, neuropsychiatric disorders, safety profile, clinical trials, pharmacodynamics, human consciousness, psychedelic safetyhttps://mindmedicinelaw.com/briefing/s-ketamine-for-adolescent-depression-in-early-onset-psychosis-20260825-35999The Psychedelic Journalen2026-08-27T15:05:42.078085+00:00S-ketamine for Adolescent Depression in Early-Onset PsychosisS-ketamine, adolescent depression, early-onset psychosis, treatment-resistant depression, suicidality, intranasal administration, psychiatric treatment, clinical trials, mental health research, psychotic disordershttps://mindmedicinelaw.com/briefing/psychedelic-doi-alters-mice-olfactory-behavior-implications-20260825-35829The Psychedelic Journalen2026-08-26T22:04:18.516880+00:00Psychedelic DOI Alters Mice Olfactory Behavior: Implicationspsychedelic research, DOI, olfactory behavior, mice study, neuroscience, sensory effects, clinical trials, serotonergic psychedelics, sensory processing, therapeutic applicationshttps://mindmedicinelaw.com/briefing/multi-omics-integration-in-mdd-toward-precision-psychiatry-20260825-35843The Psychedelic Journalen2026-08-26T22:04:08.024876+00:00Multi-Omics Integration in MDD: Toward Precision Psychiatrymulti-omics integration, major depressive disorder, precision psychiatry, biomarker-based diagnostics, personalized treatment, clinical trials, neuroimaging, genomics, mental health policy, psychiatric researchhttps://mindmedicinelaw.com/briefing/traditional-knowledge-and-pharmacology-in-ayahuasca-discovery-20260824-36144The Psychedelic Journalen2026-08-27T22:05:22.558756+00:00Traditional Knowledge and Pharmacology in Ayahuasca Discoverypsychoactive ethnobotany, ayahuasca, Amazonian admixtures, ethnopharmacological concordance, traditional pharmacopoeia, observability gradienthttps://mindmedicinelaw.com/briefing/gut-brain-axis-therapies-for-depression-in-crohn-s-disease-20260824-35799The Psychedelic Journalen2026-08-26T22:05:41.972138+00:00Gut-Brain Axis Therapies for Depression in Crohn's Diseasegut-brain axis, Crohn's disease, depression, ketamine enantiomers, microbiota-targeting compounds, vagus nerve stimulation, inflammatory bowel disease, immune activation, neuroimmune signaling, integrative treatment strategieshttps://mindmedicinelaw.com/briefing/feasibility-of-star-textstar-for-sexual-assault-survivors-20260824-35817The Psychedelic Journalen2026-08-26T22:05:27.800216+00:00Feasibility of STAR & TextSTAR for Sexual Assault Survivorssexual assault survivors, trauma recovery, STAR program, TextSTAR program, posttraumatic stress, substance misuse, psychoeducation, early intervention, mental health, opioid misusehttps://mindmedicinelaw.com/briefing/arrestins-in-gpcr-signaling-implications-for-drug-design-20260824-35830The Psychedelic Journalen2026-08-26T22:05:14.084492+00:00Arrestins in GPCR Signaling: Implications for Drug Designarrestins, GPCR signaling, drug design, neurological disorders, therapeutic strategies, biased signaling, allosteric modulators, molecular glues, cryo-electron microscopy, receptor-targeted therapieshttps://mindmedicinelaw.com/briefing/ayahuasca-s-potential-in-neuropsychiatric-drug-discovery-20260824-35831The Psychedelic Journalen2026-08-26T22:05:03.081219+00:00Ayahuasca's Potential in Neuropsychiatric Drug Discoveryayahuasca, neuropsychiatric disorders, multitarget therapeutic, drug discovery, bioactive compounds, network pharmacologyhttps://mindmedicinelaw.com/briefing/gabapentin-s-neurodegeneration-risks-emerging-insights-20260824-35844The Psychedelic Journalen2026-08-26T22:04:53.884421+00:00Gabapentin's Neurodegeneration Risks: Emerging Insightsgabapentin, neurodegeneration, neurodegenerative disorders, antiepileptic drugs, oxidative stress, excitotoxicity, SIRT1, CaMKII, cognitive decline, clinical researchhttps://mindmedicinelaw.com/briefing/proteomic-profiling-in-treatment-resistant-depression-20260824-35846The Psychedelic Journalen2026-08-26T22:04:41.470905+00:00Proteomic Profiling in Treatment-Resistant Depressiontreatment-resistant depression, extracellular vesicles, proteomic profiling, biological pathways, molecular stratification, depression research, clinical trials, neuroscience, antidepressant resistance, precision medicine